Alder Biopharmaceuticals Inc.
today announced it has received a $3.5 million milestone payment from
Bristol-Myers Squibb for the initiation of a Phase 2 clinical trial of
ALD518/BMS-945429, an investigational antibody therapeutic that blocks
interleukin-6 (IL-6), in Crohn's disease.
The milestone payment is part of the collaboration between Alder and
Bristol-Myers Squibb that was formed in 2009 for the development of
ALD518/BMS-945429. Under the collaboration agreement, Alder granted to
Bristol-Myers Squibb worldwide exclusive rights to develop and commercialize
ALD518/BMS-945429 for all potential clinical uses, with the exception of
cancer treatment and cancer supportive care, which are rights retained by
Alder.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in